Table 1.
Demographic and clinical characteristics of the sJIA patients at the time of sampling for this study
| Patient demographics | Flare (n = 10) | Quiescent (n = 9) |
|---|---|---|
| Sex, M/F | 4/6 | 6/3 |
| Age years, median (range) | 10 (4–17) | 14 (10–15) |
| Age at disease onset years, median (range) | 5.5 (2–13) | 5 (2–13) |
| Disease duration years, median (range) | 3 (1–9) | 9 (2–12) |
| CRP mg/l, median (range) | 13.6 (4–86) | <5 (<5–<5) |
| ESR mm/h, median (range) | 42 (2–95) | 4 (<1–<10) |
| Fever ± rash | 6/10 | 0/9 |
| Number of active joints, median (range) | 5.5 (0–17) | 0 (0–0) |
| Number of joints with a limitation of movement, median (range) | 6 (0–17) | 0 (0–0) |
| VAS of disease activity (physician’s), median (range), mm | 36 (1–70) | 0 (0–10) |
| VAS of overall well-being (parent’s), median (range), mm | 33.5 (0–70) | 1 (0–3) |
| Functional ability (CHAQ), median (range) | 0.66 (0–2) | 0.08 (0–0.13) |
| Pred | 2/10 | NR |
| Pred + MTX | 6/10 | NR |
| Pred + TOC | 1/10 | 2/9 |
| MTX + anakinra | 1/10 | NR |
| MTX + TOC | NR | 3/9 |
| Pred + MTX + TOC | NR | 2/9 |
M/F: male/female; VAS: visual analogue scale; CHAQ: Childhood Health Assessment Questionnaire; Pred: prednisolone; TOC: tocilizumab; NR: not reported.